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Abstract. – BACKGROUND: Von Willebrand
disease type 3, is an extremely rare condition. It
can be severe and potentially life-threatening,
particularly in pregnant women during labor
and subsequently during early puerperium. Due
to its rarity, there is no optimal treatment/man-
agement during pregnancy.
CASE: We describe two cases of pregnant
women with von Willebrand disease type 3, and
its successful surveillance and treatment with
Haemate P FVIII (human plasma-derived von
Willebrand Factor-ristocetin co-factor associat-
ed with human coagulation factor VIII), during
pregnancy, partum and puerperium.
CONCLUSIONS: Daily prophylaxis with Hae-
mate P FVIII in women with von Willebrand dis-
ease type 3, starting 2 hours before caesarean
section until the 7th day of puerperium, associ-
ated with close analytical and clinical surveil-
lance seems to be a safe clinical option.
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Abbreviations
VWD = von Willebrand disease; VWF = von Wille-
brand factor; FVIII = factor VIII; VWF:Ag = von Wille-
brand Factor antigen; VWF:RCo = von Willebrand Fac-
tor-ristocetin co-factor activity; FVIII:C = factor VIII ac-
tivity; INR = International Normalized Ratio.
Introduction
Von Willebrand disease (VWD) is the most com-
mon inherited bleeding disorder. It results from a
quantitative or qualitative deficiency of von
Willebrand factor (VWF) – a large multimeric
protein which is required for platelet adhesion
and serves as a factor VIII (FVIII) carrier.
There are three major types:
– Type 1 (70-80% of all VWD patients) is the
result of a quantitative defect of a structurally
normal VWF.
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– Type 2 (20% of VWD patients) includes sever-
al qualitative defects in VWF that affect its
multimeric structure or function. Four sub-
types exist: 2A, 2B, 2M and 2N.
– Type 3 (5-10% of VWD patients) are homozy-
gous or doubly heterozygous for two mutant
VWF alleles, which results in complete or al-
most complete absence of VWF and severe
deficiency of FVIII.
The VWF gene is located on chromosome
twelve. Types 1 and 2 are inherited as autosomal
dominant traits and type 3 is inherited as autoso-
mal recessive. Occasionally type 2 also inherits
recessively. Although the autosomal inheritance
pattern predicts that both sexes should be equally
affected, there is a higher frequency of sympto-
matic VWD in women because of the hemostatic
challenges of menstrual period, pregnancy and
delivery1-3.
Despite the prevalence of VWD being very
frequent, affecting 0.1% to 1% of the popula-
tion4-5, the prevalence of type 3 VWD, its most
severe form, is extremely low, 3 to 5 cases per
million people6.
This bleeding disorder has a very diverse clini-
cal presentation. It can vary from asymptomatic
or mild symptoms in majority of patients (type 1
or 2), to a very severe clinical condition in a mi-
nority of patients (type 3), with recurrent bleed-
ing episodes including hemarthroses, requiring
replacement therapy.
The physiological response during pregnancy
is the elevation of the factor FVIII and VWF (hy-
percoagulability state). However, in women with
VWD type 3, this physiological increase in FVIII
and VWF does not occur. Therefore, serious he-
morrhagic complications, especially during labor
and early postpartum, can be expected.
We describe the therapeutic orientation in
pregnancy and post-partum, in two women, with
VWD type 3.
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1st clinical case
32 years, primigravida, 63 kg in early pregnan-
cy, with von Willebrand disease type 3 (VWF:Ag
0%, VWF:RCo 0%, FVIII:C 3%), diagnosed at
age of 3 year-old. She had many bleeding
episodes prior to pregnancy (worth noting: metr-
orrhagia, hemarthrosis, gastrointestinal angiodys-
plasia, haemoperitoneum) that led to several treat-
ments with FVIII, VWF and red blood cell trans-
fusions. During pregnancy, prevention of bleeding
was performed with Haemate P 1.000 FVIII
[2400 International Units (IU) human plasma-de-
rived von Willebrand Factor-ristocetin co-factor
activity (VWF:RCo) and 1000 IU human coagu-
lation factor VIII activity (FVIII:C)] twice a
week, during the first 12 weeks of gestation and
restarting again at 34 weeks. Pregnancy was un-
eventful except for mild fetal growth restriction
detected at 36 weeks. Labor was induced at 38
weeks of gestation (the pregnant woman was
weighting 72 kg at this stage). A caesarean sec-
tion was performed, because of labor induction
failure (6h after the administration of Haemate P
FVIII), which resulted in a female newborn,
weighting 2370 g. The patient underwent prophy-
lactic treatment, pre and post caesarean section,
with Haemate P 1.500 FVIII (3600 IU human
plasma-derived VWF:RCo and 1500 IU human
FVIII:C) starting on the day of labor induction (2
hours before), followed by once a day, during 7
days. During labor, our anesthesiologists have
chosen intravenous analgesia and general anaes-
thesia during caesarean section. The patient was
discharged on the 7th day of puerperium, without
complications.
2nd clinical case
29 years, primigravida, 61 kg in early pregnan-
cy, with von Willebrand disease type 3 (VWF:Ag
0%, VWF:RCo 0%, FVIII:C 2%), diagnosed on
the 3rd month of life . She had several bleeding
episodes prior to pregnancy, namely epistaxis,
hemarthrosis and moderate haemoperitoneum.
Prophylaxis was made with Haemate P 1.000
FVIII (2400 IU human plasma-derived
VWF:RCo and 1000 IU human FVIII:C) once or
twice a week during the first 12 weeks of preg-
nancy and restarted again, twice a week, at 36
weeks of gestation. There were no complications
during pregnancy, including blood loss. An elec-
tive caesarean was performed at 38 weeks of ges-
tation because of breech fetal presentation. The
newborn was male, weighting 2925 g. At the
time of caesarean section the pregnant woman
was weighting 75 kg. Like on the first case, the
patient was submitted to prophylactic treatment
with Haemate P 1.500 FVIII (3.600 IU human
plasma-derived VWF:RCo and 1.500 IU human
FVIII:C) starting 2 hours before caesarean sec-
tion and once day during 7 days. As it was decid-
ed an elective caesarean, our anesthesiologists
chose to perform a general anaesthesia in this
case. The patient was discharged on the 7th day.
The puerperium was uneventful.
Discussion
Pregnancy and childbirth, in women with
VWD type 3, may be associated with severe
bleeding, predominantly during labor and in
postpartum. Mild vaginal bleeding in early preg-
nancy has also been described. In order to avoid
this bleeding in early pregnancy, and because
these two pregnant women were very anxious, it
was decided to perform prophylactic Haemate P
FVIII in the 1st trimester of pregnancy.
Although “if VWF:RCo and FVIII levels can be
monitored and maintained above 50 IU/dL during
labor and delivery, and no other coagulation defects
are present, then regional anaesthesia may be con-
sidered”7; we avoided this type of analgesia/anaes-
thesia and opted for general anaesthesia.
Despite the risk of postpartum haemorrhage can
persist for 2-3 weeks (15.7 ± 5.2 days after deliv-
ery)8, many studies state that VWF:RCo and FVIII
levels of 50 IU/dL should be achieved before de-
livery9 and maintained for 3-5 days afterward10-13.
However, caesarean section is considered a major
surgery and guidelines advise to perform prophy-
laxis for a 7-14 days postoperative period14,15.
In an attempted to give the minimum possible
amount of factor, sufficient for prophylaxis (40-
60 IU/kg body weight VWF:RCo and 20-40
IU/kg bodyweight FVIII:C)14,15 and to prevent
accumulation of dose (levels should not exceed
VWF:RCo 200 IU/dL or FVIII 250-300
IU/dL)14,15 which has been associated with some
cases of venous thromboembolism, we opted to
administer daily Haemate P 1.500 FVIII, starting
2 hours before labor induction or caesarean sec-
tion (since peak plasma levels of VWF and FVIII
usually occur at around 50 minutes and 1-1.5
hours, after injection, respectively), up to the 7th
day of puerperium. As we gave low/prophylactic
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dose of Haemate P FVIII, for a short period of
time (until the 7th day of puerperium), we chose
not to adopt antithrombotic prophylaxis with low
molecular weight heparin but rather monitor
closely these women in postpartum (the highest
peak obtained was on the first case: VWF:Ag
120%, VWF:RCo 104% and FVIII:C 166%).
After hospital discharge, we have closely ob-
served these women twice a week during the first
6 weeks of puerperium, looking for signs of
bleeding. Puerperium was uneventful.
What is the best dose and treatment duration?
How often and when is the best time that we
should monitor analytically the values of VWF:Ag,
VWF:RCo and FVIII:C? Due to the rarity of this
disease, there is still no answer to these questions.
We preferred to collect the analysis 2h after admin-
istration of Haemate P FVIII in an attempt to catch
the peak plasma levels (to prevent overdosing)
rather than collect the analysis prior to administra-
tion Haemate P FVIII since the VWF:RCo half-life
is around 9,9h16,17 and, therefore, we believe that
after 24h the values will be subtherapeutic and/or
approach null values (the average values of these
patients without medication).
Conclusions
These two uncommon cases demonstrated that
towards an uneventful caesarean section and
puerperium in a woman with VWD type 3, pro-
phylaxis in the peri-natal and during the first 7
postoperative days, associated with close clinical
and analytical surveillance can be a safe clinical
option, avoiding overtreatment side effects and/or
longer hospitalizations.
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